Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMycelx Di Regulatory News (MYX)

Share Price Information for Mycelx Di (MYX)

Share Price is delayed by 15 minutes
Get Live Data
60.50    0.00 (0.00%)
Bid:
59.00
Ask:
62.00
Spread: 3.00 (5.085%)
Market Cap: £14.74m
MYX Live PriceLast checked at - London Stock Exchange

Intraday Mycelx Di Share Chart

Year-end Update

6 Jan 2025 07:00

RNS Number : 1513S
MyCelx Technologies Corporation
06 January 2025
 

06 January 2025

 

MYCELX TECHNOLOGIES CORPORATION (AIM: MYX)

 

Year-end Update

 

MYCELX Technologies Corporation ("MYCELX" or the "Company"), the clean water and clean air technology company founded to transform the environmental impact of industry, is pleased to provide a year-end update on its core markets.

 

2024 has been a year of solid progress interspersed with timeline changes that have been outside our control. In aggregate, the continued progress that we have made in the REGEN and PFAS markets gives us great confidence in both our direction of travel and the future for the Company. Our Saudi Arabia distribution partnership, established subsequent to the sale of our Saudi Arabia operations earlier this year, is growing and diversifying its application base. The Company is pleased to report that it has been informed it will receive over $1million of the first earn out payment that is due in 2025, but will not know the full amount until the reporting period ends in February 2025.

 

Progress in the EOR / REGEN market this year include selling the Saudi Arabia operation mentioned above, the award of a very significant Middle East REGEN contract we announced in October, and three trials, one most recently operating successfully in West Texas that will continue into Q1 2025. As our success in the Middle East continues to build, the incoming Administration in the US has stated it supports US energy independence, which the Company believes will give producers increased confidence to pursue upgrades, beneficial reuse projects and other capital projects to improve water management and performance. MYCELX is well-positioned to take advantage of the opportunities in this changing market with its REGEN media and proprietary Retro-fit systems.

 

Our PFAS business won an AFFF remediation project through a global engineering company and signed a partnership with a preferred Department of Defence contractor that we announced in July. The PFAS team looks forward to wastewater and landfill leachate trials that are expected to commence in January and April of 2025, respectively, that were in different stages of implementation and design in 2024. In Q1 2025, we expect to begin the roll out of mobile PFAS systems through channel partners that will remediate PFAS contamination at small utility sites. The Company believes this is an application that can grow quickly and provide visibility for MYCELX PFAS systems.

 

The Company expects its 2024 year-end revenue to be c.a. $4.9 million, verses market expectations of $4.7 million. PBT and EBITDA is still subject to year-end closing but is expected to be broadly in line with current market expectations and the cash balance of c.a. $1.3 million slightly exceeds expectations. We look forward to continuing to grow our core market businesses in 2025 with momentum and focus, and providing progress updates in due course.

 

For further information, please contact:  

 

MYCELX Technologies Corporation

Connie Mixon, CEO

Kim Slayton, CFO

 

 

 

Tel: +1 888 306 6843

Canaccord Genuity Limited (Nominated Adviser and Broker)

Henry Fitzgerald-O'Connor

Charlie Hammond

 

Tel: +44 20 7523 8000

Celicourt Communications (Financial PR)

Mark Antelme

Jimmy Lea

Charlie Denley-Myerson

 

Tel: +44 20 7770 6424

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDSSIFFLEISELF
Date   Source Headline
26th May 20217:00 amRNSFinal Results for the year ending 31 December 2020
19th May 20217:00 amRNSInvestor Presentation
14th May 20217:00 amRNSPFAS System Validation
13th Apr 20211:49 pmRNSGrant of Options
23rd Mar 20217:00 amRNSBoard Changes
17th Mar 20213:37 pmRNSHolding(s) in Company
17th Mar 20212:35 pmRNSHolding(s) in Company
15th Mar 20217:00 amRNSHolding(s) in Company
2nd Mar 20217:00 amRNSTrading Update
18th Feb 20217:00 amRNSSale of MYCELX property in Duluth, USA
17th Feb 20214:32 pmRNSHolding(s) in Company
5th Jan 20212:32 pmRNSHolding(s) in Company
4th Jan 20217:00 amRNSHolding(s) in Company
27th Oct 20202:55 pmRNSResult of Annual Meeting
2nd Oct 20202:56 pmRNSNotice of Annual Meeting
22nd Sep 20207:00 amRNSHalf Year Results Statement
4th Sep 20207:00 amRNSAppointment of Nominated Adviser and Sole Broker
7th Aug 202011:50 amRNSDirector/PDMR Shareholding
22nd Jun 20207:00 amRNSContract extension with SABIC
19th Jun 20207:00 amRNSAnnual Financial Report
27th May 20207:00 amRNSFinal Results for the year ending 31 December 2019
11th May 20207:00 amRNSNew Project Award
14th Apr 20207:00 amRNSTrading Update
9th Mar 20207:00 amRNSClosure of Restricted Stock Line
5th Mar 20207:00 amRNSTrading Update
13th Dec 201910:25 amRNSBlock listing Interim Review
4th Nov 20197:00 amRNSTrading Update
16th Sep 20197:00 amRNSHalf Year Results Statement
20th Aug 201912:42 pmRNSHolding(s) in Company
16th Aug 20193:02 pmRNSDirector Shareholding
29th Jul 20197:00 amRNSDirectorate Changes
26th Jul 20197:00 amRNSAppointment of Nominated Adviser & Broker
22nd Jul 20191:34 pmRNSHolding(s) in Company
10th Jul 201912:57 pmRNSResult of Annual Meeting
14th Jun 20197:00 amRNSTrading Update
11th Jun 20197:00 amRNSBlock listing Interim Review
6th Jun 20197:00 amRNSIssue of Equity
31st May 20191:57 pmRNSAnnual Financial Report
13th May 20197:00 amRNSFinal Results for the year ending 31 December 2018
28th Mar 20197:00 amRNSHolding(s) in Company
15th Mar 20197:00 amRNSHolding(s) in Company
15th Mar 20197:00 amRNSHolding(s) in Company
13th Mar 20197:00 amRNSIssue of Equity
28th Feb 20194:54 pmRNSResults of Fundraising
28th Feb 20197:00 amRNSProposed $1.8 million Placing
13th Feb 201910:22 amRNSTrading Update
21st Dec 20187:00 amRNSHolding(s) in Company
11th Dec 20187:15 amRNSDirectorate Changes
7th Dec 20187:00 amRNSBlock Admission Interim Update
29th Nov 20187:00 amRNSNew Project Award and Trading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.